Nicolò Tedone

Nov 18, 2024 | jnnp.bmj.com | Maria A Rocca |Paola Valsasina |Francesco Romano |Nicolò Tedone

AbstractBackground Research on cognitive rehabilitation (CR) and aerobic exercise (EX) to improve cognition in progressive multiple sclerosis (PMS) remains limited. CogEx trial investigated the effectiveness of CR and EX in PMS: here, we present MRI substudy volumetric and task-related functional MRI (fMRI) findings. Methods Participants were randomised to: ‘CR plus EX’, ‘CR plus sham EX (EX-S)’, ‘EX plus sham CR (CR-S)’ and ‘CR-S plus EX-S‘ and attended 12-week intervention.

May 16, 2024 | jnnp.bmj.com | Maria A Rocca |Paola Valsasina |Francesco Romano |Nicolò Tedone

Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Feb 19, 2024 | journals.sagepub.com | Maria A Rocca |Paola Valsasina |Nicolò Tedone |Giulia D’Amore

IntroductionMultiple sclerosis (MS) is characterized by complex pathological substrates, resulting in non-uniform clinical manifestations and variable disease progression.1 Therefore, determining biomarkers associated with an unfavorable disease course is of paramount importance to optimize patients’ management. Magnetic resonance imaging (MRI)–derived measures are good candidates for identifying mechanisms associated with disability progression and cognitive deterioration.

Feb 6, 2024 | nature.com | Paolo Preziosa |Nicolò Tedone |Massimo Filippi

AbstractIn multiple sclerosis (MS), a non-random and clinically relevant pattern of gray matter (GM) volume loss has been described. Whether differences in regional gene expression might underlay distinctive pathological processes contributing to this regional variability has not been explored yet. Two hundred eighty-six MS patients and 172 healthy controls (HC) underwent a brain 3T MRI, a complete neurological evaluation and a neuropsychological assessment.